Delivery Order SPE2DB22D2206-SPE2DB25FGN06

Award Date 4/10/25
Potential Completion Date 5/1/25
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $2,343.59 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract provides the TEZSPIRE 210 MG/1.91 ML PEN 1.91ML medication with an ultimate completion date of April 18, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a $2,343.59 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TEZSPIRE 210 MG/1.91 ML PEN 1.91ML, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of March 26, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The award, valued at $2,265.29, is for the supply of TEZSPIRE 210 MG/1.91 ML PEN 1.91ML, a pharmaceutical product. The delivery order falls under a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of TEZSPIRE 210 MG/1.91 ML PEN 1.91ML. The contract has a firm fixed price of $2,343.59 and an ultimate completion date of February 19, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,687.18 contract is for the supply of TEZSPIRE 210 MG/1.91 ML PEN 1.91ML, a specialty pharmaceutical product, with a period of performance through May 2, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of TEZSPIRE 210 MG/1.91 ML PEN 1.91ML. The award, valued at $2,265.29, has a completion date of September 12, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TEZSPIRE 210 MG/1.91 ML PEN 1.91ML, a pharmaceutical product, with a ceiling value of $2,343.59 and a period of performance through March 7, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation indicated. AmerisourceBergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of the medication TEZSPIRE 210 MG/1.91 ML PEN 1.91ML. It is a firm fixed-price contract with a ceiling value of $14,061.54 and a performance period ending on May 22, 2025. The contract was awarded on May 1, 2025 and is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a larger Indefinite...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,687.18, is for the supply of the specialty medication TEZSPIRE 210 MG/1.91 ML PEN. The contract has a completion date of February 20, 2025 and is a Firm Fixed Price contract. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication TEZSPIRE 210 MG/1.91 ML PEN 1.91ML. The contract has a ceiling value of $9,374.36 and a period of performance through May 16, 2025. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FGN06
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,343.59, is for the supply of the medication TEZSPIRE 210 MG/1.91 ML PEN 1.91ML. The contract has an ultimate completion date of May 1, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This delivery order is not designated as a set-aside contract.

Generated 7/17/25, 6:04 PM